uhs-8k_20221021.htm
false 0000352915 0000352915 2022-10-21 2022-10-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2022

 

UNIVERSAL HEALTH SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

1-10765

 

23-2077891

(State or other jurisdiction of

 

(Commission

 

(I.R.S. Employer

Incorporation or Organization)

 

File Number)

 

Identification No.)

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, Pennsylvania 19406

(Address of principal executive office) (Zip Code)

Registrant’s telephone number, including area code (610) 768-3300

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class B Common Stock

UHS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 


 

 

Item 2.02 Results of Operations and Financial Condition

On October 25, 2022, Universal Health Services, Inc. issued the press release attached hereto as Exhibit 99.1.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure and Compensatory Arrangements of a Certain Officer

(b) (e)On October 21, 2022, Marvin G. Pember, Executive Vice President of the Company and President, Acute Care, who has been with the Company since 2011, informed us of his intention to retire from his position after a transition period following the commencement of employment of Edward H. Sim, as described below.  A compensatory arrangement with Mr. Pember is currently being discussed.

Item 8.01 Other Events.

The Company also announced that Mr. Sim has been appointed to the role of Executive Vice President of the Company and President, Acute Care, with a planned commencement date of December 5, 2022.  Mr. Sim most recently served as Chief Operating Officer at Centura Health where he led the system’s three operating groups, clinical delivery and shared services with annual revenues of approximately $5 billion. Prior to joining Centura Health, Mr. Sim served in senior leadership roles of increasing responsibility for 11 years at Baptist Health in Jacksonville, Florida.  

A copy of the Company’s press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

 

 

99.1

  

Universal Health Services, Inc., press release (earnings), dated October 25, 2022.

99.2

  

Universal Health Services, Inc., press release, dated October 25, 2022.

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

Exhibit Index

 

Exhibit No.

  

Exhibit

 

 

99.1

  

Universal Health Services, Inc., press release (earnings), dated October 25, 2022.

99.2

  

Universal Health Services, Inc., press release, dated October 25, 2022.

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Universal Health Services, Inc.

 

By:

 

/s/ Steve Filton

Name: Steve Filton

Title: Executive Vice President and

            Chief Financial Officer

Date: October 25, 2022

 

 

 

 

uhs-ex991_6.htm

Exhibit 99.1

FOR IMMEDIATE RELEASE

October 25, 2022

 

CONTACT:

Steve Filton

 

Chief Financial Officer

 

610-768-3300

 

 

UNIVERSAL HEALTH SERVICES, INC.

REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS

 

Consolidated Results of Operations, As Reported and As Adjusted  – Three-month periods ended September 30, 2022 and 2021:

KING OF PRUSSIA, PA – Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $182.8 million, or $2.50 per diluted share, during the third quarter of 2022, as compared to $218.4 million, or $2.60 per diluted share, during the third quarter of 2021. Net revenues increased by 5.7% to $3.336 billion during the third quarter of 2022 as compared to $3.156 billion during the third quarter of 2021.

As reflected on the Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”), our adjusted net income attributable to UHS during the third quarter of 2022 was $185.8 million, or $2.54 per diluted share, as compared to $224.1 million, or $2.67 per diluted share, during the third quarter of 2021.  

Included in our reported and adjusted net income attributable to UHS during the three and nine-month periods ended September 30, 2022 was an aggregate of $25.3 million in Quality Incentive Fund (“QIF”) payments, applicable to the period of September 1, 2020 to August 31, 2021, recorded by certain of our acute care hospitals located in Texas in connection with the state’s Uniform Hospital Rate Increase Program (“UHRIP”) program. This revenue was earned pursuant to contract terms with various Medicaid managed care plans which requires the annual payout of QIF funds when a managed care service delivery area’s actual claims based UHRIP payments are less than targeted UHRIP payments for a specific rate year. We anticipate that these hospitals may be entitled to an additional $5 million of QIF revenue during the fourth quarter of 2022, increasing the 2022 aggregate to approximately $30 million.  We also anticipate that these hospitals may be entitled to a comparable amount of aggregate QIF revenue during 2023.

As reflected on the Supplemental Schedule, included in our reported results during the third quarter of 2022, was an unfavorable after-tax unrealized loss of $3.0 million, or $.04 per diluted share, ($3.9 million pre-tax which is included in “Other (income) expense, net”), resulting from a decrease in the market value of certain equity securities.  

As reflected on the Supplemental Schedule, included in our reported results during the third quarter of 2021, was a net aggregate unfavorable after-tax impact of $5.8 million, or $.07 per diluted share, consisting primarily of the following: (i) an after-tax charge of $12.9 million, or $.15 per diluted share, ($16.8 million pre-tax which is included in “Other (income) expense, net”) recorded in connection with costs related to extinguishment of debt, partially offset by; (ii) an after-tax unrealized gain of $6.8 million, or $.08 per diluted share, ($8.9 million pre-tax which is included in “Other (income) expense, net”), resulting from an increase in the market value of shares of certain equity securities.  

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”, NCI is net income attributable to noncontrolling interests), was $421.7 million during the third quarter of 2022, as compared to $441.5 million during the third quarter of 2021. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, was $427.8 million during the third quarter of 2022, as compared to $448.2 million during the third quarter of 2021.

Consolidated Results of Operations, As Reported and As Adjusted  – Nine-month periods ended September 30, 2022 and 2021:


Reported net income attributable to UHS was $500.8 million, or $6.71 per diluted share, during the first nine months 2022, as compared to $752.5 million, or $8.83 per diluted share, during the first nine months of 2021. Net revenues increased by 6.3% to $9.952 billion during the first nine months of 2022 as compared to $9.367 billion during the comparable period of 2021.

Included in our reported and adjusted net income attributable to UHS during the nine-month period ended September 30, 2021 was a net favorable after-tax impact of approximately $31.2 million, or $.37 per diluted share, from the following: (i) a favorable after-tax impact of $47.7 million, or $.56 per diluted share, resulting from approximately $62 million of revenues recorded during the second and third quarters of 2021 ($55 million and $7 million, respectively) in connection with the Kentucky Medicaid managed care hospital rate increase program (covering the period of July 1, 2020 to June 30, 2021); (ii) an unfavorable after-tax impact of approximately $31.0 million, or $.36 per diluted share, resulting from a $41 million increase to our reserves for self-insured professional and general liability claims recorded during the second and third quarters of 2021 ($36 million and $5 million, respectively); (iii) an aggregate favorable after-tax impact of $22.1 million, or $.26 per diluted share, resulting from aggregate commercial insurance proceeds of approximately $29 million recorded during the second and third quarters of 2021 ($19 million and $10 million, respectively) in connection with a previously incurred information technology incident and the COVID-19 pandemic, and; (iv) an estimated unfavorable after-tax impact of approximately $7.6 million (approximately $10 million pre-tax), or $.09 per diluted share, resulting from damage sustained from Hurricane Ida during the third quarter of 2021.

As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the nine-month period ended September 30, 2022 was $513.1 million, or $6.88 per diluted share, as compared to $756.6 million, or $8.88 per diluted share, during the nine-month period ended September 30, 2021.  

As reflected on the Supplemental Schedule, included in our reported results during the first nine months of 2022, was an unfavorable after-tax unrealized loss of $12.4 million, or $.17 per diluted share, ($16.1 million pre-tax which is included in “Other (income) expense, net”), resulting from a decrease in the market value of certain equity securities.  

As reflected on the Supplemental Schedule, included in our reported results during the nine-month period ended September 30, 2021, was a net aggregate unfavorable after-tax impact of $4.1 million, or $.05 per diluted share, consisting of the following: (i) an after-tax charge of $12.9 million, or $.15 per diluted share, ($16.8 million pre-tax which is included in “Other (income) expense, net”) recorded in connection with costs related to extinguishment of debt, partially offset by; (ii) an after-tax unrealized gain of $6.3 million, or $.07 per diluted share, ($8.2 million pre-tax which is included in “Other (income) expense, net”) resulting from an increase in the market value of shares of certain equity securities, and; (iii) a favorable after-tax impact of $2.5 million, or $.03 per diluted share, resulting from ASU 2016-09 “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”).

As calculated on the attached Supplemental Schedule, our EBITDA net of NCI was $1.175 billion during the first nine months of 2022, as compared to $1.450 billion during the first nine months of 2021. Our Adjusted EBITDA net of NCI was $1.190 billion during the first nine months of 2022, as compared to $1.448 billion during the first nine months of 2021.

Acute Care Services – Three and nine-month periods ended September 30, 2022 and 2021:

During the third quarter of 2022, at our acute care hospitals owned during both periods (“same facility basis”), adjusted admissions (adjusted for outpatient activity) increased by 1.9% while adjusted patient days decreased by 5.0%, as compared to the third quarter of 2021. At these facilities, during the third quarter of 2022, net revenue per adjusted admission decreased by 2.5% while net revenue per adjusted patient day increased 4.5%, as compared to the third quarter of 2021. Net revenues generated from our acute care services on a same facility basis increased by 0.9% during the third quarter of 2022, as compared to the third quarter of 2021.  

During the nine-month period ended September 30, 2022, at our acute care hospitals on a same facility basis, adjusted admissions increased by 2.2% while adjusted patient days increased by 0.6%, as compared to the comparable nine-month period of 2021. At these facilities, during the first nine months of 2022, net revenue per adjusted admission increased by 1.0% while net revenue per adjusted patient day increased by 2.6%, as compared to the comparable nine-month period of 2021. Net revenues generated from our acute care services


on a same facility basis increased by 4.6% during the first nine months of 2022, as compared to the comparable nine-month period of 2021.  

Behavioral Health Care Services – Three and nine-month periods ended September 30, 2022 and 2021:

During the third quarter of 2022, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 4.0% while adjusted patient days increased by 3.3%, as compared to the third quarter of 2021. At these facilities, during the third quarter of 2022, net revenue per adjusted admission increased by 4.2% and net revenue per adjusted patient day increased by 5.0%, as compared to the third quarter of 2021.  Net revenues generated from our behavioral health care services increased by 8.4% during the third quarter of 2022, as compared to the third quarter of 2021.

During the nine-month period ended September 30, 2022, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 0.6% while adjusted patient days increased by 0.9%, as compared to the comparable nine-month period of 2021. At these facilities, during the first nine months of 2022, net revenue per adjusted admission increased by 4.2% and net revenue per adjusted patient day increased by 3.9%, as compared to the comparable nine-month period of 2021. Net revenues generated from our behavioral health care services increased by 4.1% during the first nine months of 2022, as compared to the comparable period of 2021.

COVID-19 and Staffing Shortage

The impact of the COVID-19 pandemic, which began during the second half of March, 2020, has had a material effect on our operations and financial results since that time. The length and extent of the disruptions caused by the COVID‑19 pandemic are currently unknown; however, we expect such disruptions to continue into the future. Since the future volumes and severity of COVID-19 patients remain highly uncertain and subject to change, including potential increases in future COVID-19 patient volumes caused by new variants of the virus, as well as related pressures on staffing and wage rates, we are not able to fully quantify the impact that these factors will have on our future financial results.  However, future developments related to the COVID-19 pandemic could continue to materially affect our financial performance.   

The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. Like others in the healthcare industry, we continue to experience a shortage of nurses and other clinical staff and support personnel at our acute care and behavioral health care hospitals in many geographic areas. In some areas, the labor scarcity is putting a strain on our resources and staff, which has required us to utilize higher‑cost temporary labor and pay premiums above standard compensation for essential workers. This staffing shortage has required us to hire expensive temporary personnel and/or enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel. At certain facilities, particularly within our behavioral health care segment, we have been unable to fill all vacant positions and, consequently, have been required to limit patient volumes. These factors, which had a material unfavorable impact on our results of operations during the first nine months of 2022, are expected to continue to have an unfavorable material impact on our results of operations for the foreseeable future.    

However, as previously disclosed on June 30, 2022, our revised operating results forecast for the balance of 2022 assumed that staffing vacancies and the corresponding premium pay expenditures continue to sequentially decline in the second half of the year and that non-COVID patient volumes will incrementally improve, although both at a slower pace than our original forecast anticipated. We believe these assumptions will be bolstered by our continuing recruitment and retention initiatives, by changes to our historical patient care models, by other cost cutting measures and by aggressive contractual negotiations and renegotiations with our managed care payers.  

Net Cash Provided by Operating Activities and Liquidity:

Net Cash Provided by Operating Activities:

During the nine-month period ended September 30, 2022, our net cash provided by operating activities was $699 million as compared to $562 million during the comparable nine-month period of 2021.  The $137 million net increase in our net cash provided by operating activities during the first nine months of 2022, as compared to the first nine months of 2021, was due to: (i) a favorable change of $695 million resulting from the


early return of Medicare accelerated payments which were received during 2020 and repaid during the first quarter of 2021, partially offset by; (ii) an unfavorable change of $245 million resulting from a decrease in net income plus depreciation and amortization expense, stock-based compensation expense, gain/loss on sales of assets and businesses, costs related to extinguishment of debt and provision for asset impairment; (iii) an unfavorable change of $227 million from other working capital accounts due primarily to the timing of disbursements for accrued compensation; (iv) an unfavorable change of $126 million in accounts receivable, and; (v) $40 million of other combined net favorable changes.    

Liquidity:

As of September 30, 2022, we had $1.007 billion of aggregate available borrowing capacity pursuant to our $1.2 billion revolving credit facility, net of outstanding borrowings and letters of credit.       

Stock Repurchase Program:

As of December 31, 2021, we had an aggregate remaining repurchase authorization of approximately $358 million pursuant to our stock repurchase program. In February of 2022, our Board of Directors authorized a $1.4 billion increase to the program. As of September 30, 2022, we had an aggregate available repurchase authorization of $1.05 billion. 

Pursuant to the terms of our stock repurchase program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions. During the third quarter of 2022, we have repurchased approximately 1.60 million shares at an aggregate cost of approximately $157.9 million (approximately $99 per share) pursuant to the program.  During the first nine months of 2022, we have repurchased approximately 5.85 million shares at an aggregate cost of approximately $703.7 million (approximately $120 per share) pursuant to the program.

Conference call information:        

We will hold a conference call for investors and analysts at 9:00 a.m. eastern time on October 26, 2022. A live webcast of the call will be available on our website at www.uhs.com. To participate via telephone, please register in advance by accessing this link.  Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

One of the nation’s largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2021 were approximately $12.6 billion. In 2022, UHS was again recognized as one of the World’s Most Admired Companies by Fortune; ranked #297 on the Fortune 500; and in 2021, ranked #307 on Forbes’ list of America’s Largest Public Companies.

Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones.  Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has over 89,000 employees and through its subsidiaries operates 28 acute care hospitals, 331 behavioral health facilities, 41 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 U.S. states, Washington, D.C., Puerto Rico and the United Kingdom. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT).  For additional information visit www.uhs.com.

This press release contains forward-looking statements based on current management expectations.  Numerous factors, including those disclosed herein, those related to the anticipated impact of COVID-19 on our operations and financial results, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 2-Forward Looking Statements and Risk Factors in our Form 10-Q for the quarter ended June 30, 2022 and in Item 1A-Risk Factors and in Item 7-Forward-


Looking Statements and Risk Factors in our Form 10-K for the year ended December 31, 2021), may cause the results to differ materially from those anticipated in the forward-looking statements.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof.  We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Many of the factors that could affect our future results are beyond our control or ability to predict, including the impact of the COVID-19 pandemic. Our future operations and financial results will likely be materially unfavorably impacted by developments related to COVID-19 including, but not limited to, the potential impact on future COVID-19 patient volumes resulting from new variants of the virus, the length of time and severity of the spread of the pandemic; the volume of cancelled or rescheduled elective procedures and the volume of COVID-19 patients treated at our hospitals and other healthcare facilities; measures we are taking to respond to the COVID-19 pandemic; the impact of government and administrative regulation and stimulus on the hospital industry and potential retrospective adjustment in future periods of CARES Act and other grant income revenues recorded as revenues in prior periods; declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential disruptions to our clinical staffing and shortages and disruptions related to supplies required for our employees and patients; potential increases to expenses and other costs related to staffing, supply chain, construction and medical equipment costs and other expenditures resulting from inflation; the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financing perspective; and changes in general economic conditions nationally and regionally in our markets resulting from the COVID-19 pandemic. In addition, please see the disclosure above in COVID-19 and Staffing Shortage, in connection with the nationwide shortage of nurses and other clinical staff and support personnel which has had, and is expected to continue to have, a material unfavorable impact on our results of operations.  

We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill and long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-Q for the quarter ended June 30, 2022 and our Report on Form 10-K for the year ended December 31, 2021. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

 

 

(more)

 



 

 

 

Universal Health Services, Inc.

 

Consolidated Statements of Income

 

(in thousands, except per share amounts)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months

 

 

Nine months

 

 

 

ended September 30,

 

 

ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net revenues

 

$

3,336,027

 

 

 

3,155,999

 

 

$

9,952,390

 

 

 

9,366,866

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating charges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries, wages and benefits

 

 

1,677,431

 

 

 

1,556,448

 

 

 

5,061,173

 

 

 

4,542,156

 

Other operating expenses

 

 

837,241

 

 

 

754,072

 

 

 

2,526,060

 

 

 

2,233,590

 

Supplies expense

 

 

366,337

 

 

 

367,834

 

 

 

1,092,403

 

 

 

1,052,977

 

Depreciation and amortization

 

 

145,874

 

 

 

134,462

 

 

 

433,508

 

 

 

399,850

 

Lease and rental expense

 

 

33,264

 

 

 

28,375

 

 

 

97,075

 

 

 

88,848

 

 

 

 

3,060,147

 

 

 

2,841,191

 

 

 

9,210,219

 

 

 

8,317,421

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from operations

 

 

275,880

 

 

 

314,808

 

 

 

742,171

 

 

 

1,049,445

 

Interest expense, net

 

 

35,653

 

 

 

21,199

 

 

 

83,002

 

 

 

64,455

 

Other (income) expense, net

 

 

6,015

 

 

 

6,719

 

 

 

15,244

 

 

 

(1,575

)

Income before income taxes

 

 

234,212

 

 

 

286,890

 

 

 

643,925

 

 

 

986,565

 

Provision for income taxes

 

 

57,401

 

 

 

67,515

 

 

 

157,312

 

 

 

232,844

 

Net income

 

 

176,811

 

 

 

219,375

 

 

 

486,613

 

 

 

753,721

 

Less:  Net income (loss) attributable to noncontrolling interests ("NCI")

 

 

(6,003

)

 

 

1,024

 

 

 

(14,176

)

 

 

1,255

 

Net income attributable to UHS

 

$

182,814

 

 

$

218,351

 

 

$

500,789

 

 

$

752,466

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share attributable to UHS (a)

 

$

2.52

 

 

$

2.65

 

 

$

6.78

 

 

$

8.96

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share attributable to UHS (a)

 

$

2.50

 

 

$

2.60

 

 

$

6.71

 

 

$

8.83

 

 



 

Universal Health Services, Inc.

 

Footnotes to Consolidated Statements of Income

 

(in thousands, except per share amounts)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months

 

 

Nine months

 

 

 

ended September 30,

 

 

ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

(a) Earnings per share calculation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to UHS

 

$

182,814

 

 

$

218,351

 

 

$

500,789

 

 

$

752,466

 

Less: Net income attributable to unvested restricted share grants

 

 

(179

)

 

 

(396

)

 

 

(592

)

 

 

(1,609

)

Net income attributable to UHS - basic and diluted

 

$

182,635

 

 

$

217,955

 

 

$

500,197

 

 

$

750,857

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares - basic

 

 

72,595

 

 

 

82,262

 

 

 

73,769

 

 

 

83,756

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share attributable to UHS:

 

$

2.52

 

 

$

2.65

 

 

$

6.78

 

 

$

8.96

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares

 

 

72,595

 

 

 

82,262

 

 

 

73,769

 

 

 

83,756

 

Add: Other share equivalents

 

 

465

 

 

 

1,411

 

 

 

743

 

 

 

1,275

 

Weighted average number of common shares and equiv. - diluted

 

 

73,060

 

 

 

83,673

 

 

 

74,512

 

 

 

85,031

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share attributable to UHS:

 

$

2.50

 

 

$

2.60

 

 

$

6.71

 

 

$

8.83

 

 


 

Universal Health Services, Inc.

 

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")

 

For the Three Months ended September 30, 2022 and 2021

 

(in thousands, except per share amounts)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

% Net

 

 

Three months ended

 

 

% Net

 

 

September 30, 2022

 

 

revenues

 

 

September 30, 2021

 

 

revenues

 

Net income attributable to UHS

$

182,814

 

 

 

 

 

 

$

218,351

 

 

 

 

 

   Depreciation and amortization

 

145,874

 

 

 

 

 

 

 

134,462

 

 

 

 

 

   Interest expense, net

 

35,653

 

 

 

 

 

 

 

21,199

 

 

 

 

 

   Provision for income taxes

 

57,401

 

 

 

 

 

 

 

67,515

 

 

 

 

 

EBITDA net of NCI

$

421,742

 

 

 

12.6

%

 

$

441,527

 

 

 

14.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expense, net

 

6,015

 

 

 

 

 

 

 

6,719

 

 

 

 

 

Adjusted EBITDA net of NCI

$

427,757

 

 

 

12.8

%

 

$

448,246

 

 

 

14.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenues

$

3,336,027

 

 

 

 

 

 

$

3,155,999

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Calculation of Adjusted Net Income Attributable to UHS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

 

 

Three months ended

 

 

September 30, 2022

 

 

September 30, 2021

 

 

 

 

 

 

Per

 

 

 

 

 

 

Per

 

 

Amount

 

 

Diluted Share

 

 

Amount

 

 

Diluted Share

 

Net income attributable to UHS

$

182,814

 

 

$

2.50

 

 

$

218,351

 

 

$

2.60

 

Plus/minus after-tax adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (gain) loss on equity securities

 

2,974

 

 

 

0.04

 

 

 

(6,785

)

 

 

(0.08

)

Debt extinguishment costs

 

-

 

 

 

-

 

 

 

12,884

 

 

 

0.15

 

Impact of ASU 2016-09

 

-

 

 

 

-

 

 

 

(323

)

 

 

-

 

Subtotal adjustments

 

2,974

 

 

 

0.04

 

 

 

5,776

 

 

 

0.07

 

Adjusted net income attributable to UHS

$

185,788

 

 

$

2.54

 

 

$

224,127

 

 

$

2.67

 

 

 

 

 

 

 

 

 



 

Universal Health Services, Inc.

 

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")

 

For the Nine Months ended September 30, 2022 and 2021

 

(in thousands, except per share amounts)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine months ended

 

 

% Net

 

 

Nine months ended

 

 

% Net

 

 

September 30, 2022

 

 

revenues

 

 

September 30, 2021

 

 

revenues

 

Net income attributable to UHS

$

500,789

 

 

 

 

 

 

$

752,466

 

 

 

 

 

   Depreciation and amortization

 

433,508

 

 

 

 

 

 

 

399,850

 

 

 

 

 

   Interest expense, net

 

83,002

 

 

 

 

 

 

 

64,455

 

 

 

 

 

   Provision for income taxes

 

157,312

 

 

 

 

 

 

 

232,844

 

 

 

 

 

EBITDA net of NCI

$

1,174,611

 

 

 

11.8

%

 

$

1,449,615

 

 

 

15.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expense, net

 

15,244

 

 

 

 

 

 

 

(1,575

)

 

 

 

 

Adjusted EBITDA net of NCI

$

1,189,855

 

 

 

12.0

%

 

$

1,448,040

 

 

 

15.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenues

$

9,952,390

 

 

 

 

 

 

$

9,366,866

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Calculation of Adjusted Net Income Attributable to UHS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine months ended

 

 

Nine months ended

 

 

September 30, 2022

 

 

September 30, 2021

 

 

 

 

 

 

Per

 

 

 

 

 

 

Per

 

 

Amount

 

 

Diluted Share

 

 

Amount

 

 

Diluted Share

 

Net income attributable to UHS

$

500,789

 

 

$

6.71

 

 

$

752,466

 

 

$

8.83

 

Plus/minus after-tax adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (gain) loss on equity securities

 

12,358

 

 

 

0.17

 

 

 

(6,255

)

 

 

(0.07

)

Debt extinguishment costs

 

-

 

 

 

-

 

 

 

12,884

 

 

 

0.15

 

Impact of ASU 2016-09

 

-

 

 

 

-

 

 

 

(2,522

)

 

 

(0.03

)

Subtotal adjustments

 

12,358

 

 

 

0.17

 

 

 

4,107

 

 

 

0.05

 

Adjusted net income attributable to UHS

$

513,147

 

 

$

6.88

 

 

$

756,573

 

 

$

8.88

 

 

 


 

Universal Health Services, Inc.

 

Condensed Consolidated Balance Sheets

 

(in thousands)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

74,571

 

 

$

115,301

 

Accounts receivable, net

 

 

1,902,472

 

 

 

1,746,635

 

Supplies

 

 

217,818

 

 

 

206,839

 

Other current assets

 

 

261,698

 

 

 

194,781

 

Total current assets

 

 

2,456,559

 

 

 

2,263,556

 

 

 

 

 

 

 

 

 

 

Property and equipment

 

 

11,103,596

 

 

 

10,770,702

 

Less: accumulated depreciation

 

 

(5,167,198

)

 

 

(4,896,427

)

 

 

 

5,936,398

 

 

 

5,874,275

 

Other assets:

 

 

 

 

 

 

 

 

Goodwill

 

 

3,874,021

 

 

 

3,962,624

 

Deferred income taxes

 

 

55,789

 

 

 

45,707

 

Right of use assets-operating leases

 

 

457,209

 

 

 

367,477

 

Deferred charges

 

 

6,336

 

 

 

6,525

 

Other

 

 

592,588

 

 

 

573,379

 

Total Assets

 

$

13,378,900

 

 

$

13,093,543

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Current maturities of long-term debt

 

$

66,307

 

 

$

48,409

 

Accounts payable and other liabilities

 

 

1,795,004

 

 

 

1,860,496

 

Operating lease liabilities

 

 

70,146

 

 

 

64,484

 

Federal and state taxes

 

 

7,743

 

 

 

10,720

 

Total current liabilities

 

 

1,939,200

 

 

 

1,984,109

 

 

 

 

 

 

 

 

 

 

Other noncurrent liabilities

 

 

500,119

 

 

 

464,759

 

Operating lease liabilities noncurrent

 

 

392,582

 

 

 

304,624

 

Long-term debt

 

 

4,638,356

 

 

 

4,141,879

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interest

 

 

4,563

 

 

 

5,119

 

 

 

 

 

 

 

 

 

 

UHS common stockholders' equity

 

 

5,855,353

 

 

 

6,089,664

 

Noncontrolling interest

 

 

48,727

 

 

 

103,389

 

Total equity

 

 

5,904,080

 

 

 

6,193,053

 

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders' Equity

 

$

13,378,900

 

 

$

13,093,543

 

 


 

Universal Health Services, Inc.

 

Consolidated Statements of Cash Flows

 

(in thousands)

 

(unaudited)

 

 

Nine months

 

 

ended September 30,

 

 

2022

 

 

2021

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

Net income

$

486,613

 

 

$

753,721

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation & amortization

 

433,508

 

 

 

399,850

 

(Gain) loss on sale of assets and businesses

 

584

 

 

 

(4,803

)

Costs related to extinguishment of debt

 

0

 

 

 

16,831

 

Stock-based compensation expense

 

62,741

 

 

 

55,548

 

Provision for asset impairment

 

0

 

 

 

7,195

 

Changes in assets & liabilities, net of effects from acquisitions and dispositions:

 

 

 

 

 

 

 

Accounts receivable

 

(155,142

)

 

 

(29,079

)

Accrued interest

 

529

 

 

 

3,714

 

Accrued and deferred income taxes

 

(4,900

)

 

 

(52,727

)

Other working capital accounts

 

(173,903

)

 

 

52,616

 

Medicare accelerated payments and deferred CARES Act and other grants

 

2,921

 

 

 

(697,393

)

Other assets and deferred charges

 

22,219

 

 

 

(34,038

)

Other

 

(23,358

)

 

 

9,607

 

Accrued insurance expense, net of commercial premiums paid

 

134,908

 

 

 

140,702

 

Payments made in settlement of self-insurance claims

 

(88,001

)

 

 

(60,069

)

Net cash provided by operating activities

 

698,719

 

 

 

561,675

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

Property and equipment additions

 

(569,555

)

 

 

(666,025

)

Proceeds received from sales of assets and businesses

 

12,001

 

 

 

21,143

 

Acquisition of businesses and property

 

(18,666

)

 

 

(39,391

)

Inflows from foreign exchange contracts that hedge our net U.K. investment

 

177,214

 

 

 

4,261

 

Decrease in capital reserves of commercial insurance subsidiary

 

100

 

 

 

100

 

Costs incurred for purchase of information technology applications, net of refunds

 

0

 

 

 

20,202

 

Net cash used in investing activities

 

(398,906

)

 

 

(659,710

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

Repayments of long-term debt

 

(194,115

)

 

 

(3,026,888

)

Additional borrowings

 

705,321

 

 

 

2,912,374

 

Financing costs

 

(2,541

)

 

 

(17,967

)

Repurchase of common shares

 

(723,384

)

 

 

(770,665

)

Dividends paid

 

(44,192

)

 

 

(50,284

)

Issuance of common stock

 

10,399

 

 

 

10,108

 

Profit distributions to noncontrolling interests

 

(5,426

)

 

 

(5,744

)

Purchase (sale) of ownership interests by (from) minority member

 

(49,089

)

 

 

13,046

 

Net cash used in financing activities

 

(303,027

)

 

 

(936,020

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

(10,339

)

 

 

(682

)

Decrease in cash, cash equivalents and restricted cash

 

(13,553

)

 

 

(1,034,737

)

Cash, cash equivalents and restricted cash, beginning of period

 

178,934